The IDIBAPS research institute has worldwide renowned expertise inbiomedical research and offers the highest quality platforms to ensure the best quality of BLB services.

BLB was selected to be part of the 2nd edition of this entrepreneurship program organized by Caixa Capital Risk and La Caixa Foundation. The program helped and fully supported the generation and development of BLB.

Conatus is a biotechnology company aimed at developing and commercializing novel medicines to treat liver disease. BLB conducted important preclinical research into the mechanism of Conatus’ lead compound emricasan in the field of liver cirrhosis & portal hypertension.

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative medicines for patients living with life-threatening diseases. Gilead trusts a significant part of its pre-clinical research in liver diseases to BLB, this partnership enhances Gilead’s ability to develop new treatments for aCLD as efficiently as possible.

Brudylab is a nutraceutical company specialized in medical supplementation based on the health benefits of docosahexaenoic acid (DHA). BLB supports the pre-clinical research & clinical development of BrudyLab’s DHA to treat chronic liver disease.

Is a biotech company focused on providing ready to use in vitro tools for R+D in the ADME-tox field. With BLB we provide superior analysis of hepatic function and toxicity.

Surrozen is a biotech company developing innovative regenerative antibodies to repair tissues and organs damaged by serious diseases. BLB provides cutting-edge research services to enhance the characterization of regenerative pathways in chronic liver disease.

GAT Therapeutics is an early stage biopharma targeting fibrosis and age-related diseases. BLB develops the pre-clinical research of GATTx characterizing the effects of its leading drug candidate GTX-011 for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).

Inventiva is a clinical stage biopharmaceutical with expertise in fibrosis, oncology and orphan diseases. BLB develops pre-clinical research to ascertain the effects and underlying mechanisms of Inventiva’s lead compound lanifibranor as therapeutic for chronic liver disease and portal hypertension.